Eli Lilly’s $3.2B acquisition of Morphic put renewed focus on Integrin α4β7 as a target in IBD. In collaboration with Sleuth, we assessed the competitive landscape and key risks for MORF-057—including its differentiation potential as a gut-selective oral therapy. The post Scientific insights: The Integrin α4β7 landscape in IBD appeared first on Vibe Bio .
Discovery
Learnings
- auto_storiesStories
- categoryAreas
- helpFAQ
- forumConversations
- descriptionPapers
- mailNewsletters
- video_libraryVideos
- timelineTimeline
Guidance
- codeTechnology of APIs
- business_centerBusiness of APIs
- campaignEvangelism of APIs
- gavelGovernance of APIs
- historyHistory of APIs
- account_balancePolitics of APIs
Toolbox
- domainProviders
- apiAPIs
- cloudSolutions
- buildTools
- verifiedStandards
- gavelRegulations
- horizontal_ruleHeaders
- layersOverlays
- extensionExtensions
- schemaSchema
- policyPolicies
- ruleRules